The Accelerated Approval Program for Cancer Drugs -- Finding the Right Balance.

The article focuses on the Accelerated Approval Program for cancer drugs and the need to strike the right balance between expediting drug approvals based on surrogate measures and ensuring clinical benefits are confirmed in subsequent trials. Topics include the challenges and issues with the current program, proposed changes to the program, and the importance of safeguarding patient interests while accelerating drug development.